Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
45.36
+0.54 (1.20%)
At close: Jan 29, 2026, 4:00 PM EST
45.35
-0.01 (-0.02%)
After-hours: Jan 29, 2026, 4:20 PM EST
Collegium Pharmaceutical Revenue
Collegium Pharmaceutical had revenue of $209.36M in the quarter ending September 30, 2025, with 31.42% growth. This brings the company's revenue in the last twelve months to $757.07M, up 26.34% year-over-year. In the year 2024, Collegium Pharmaceutical had annual revenue of $631.45M with 11.41% growth.
Revenue (ttm)
$757.07M
Revenue Growth
+26.34%
P/S Ratio
1.91
Revenue / Employee
$2,120,636
Employees
357
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 631.45M | 64.68M | 11.41% |
| Dec 31, 2023 | 566.77M | 102.83M | 22.17% |
| Dec 31, 2022 | 463.93M | 187.07M | 67.56% |
| Dec 31, 2021 | 276.87M | -33.15M | -10.69% |
| Dec 31, 2020 | 310.02M | 13.32M | 4.49% |
| Dec 31, 2019 | 296.70M | 16.29M | 5.81% |
| Dec 31, 2018 | 280.41M | 251.94M | 884.73% |
| Dec 31, 2017 | 28.48M | 26.77M | 1,564.29% |
| Dec 31, 2016 | 1.71M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.28B |
| Phibro Animal Health | 1.40B |
| Evotec SE | 887.40M |
| ANI Pharmaceuticals | 826.88M |
| Amphastar Pharmaceuticals | 723.31M |
| BioCryst Pharmaceuticals | 599.82M |
| Alvotech | 573.35M |
| Dynavax Technologies | 330.51M |
COLL News
- 7 days ago - Collegium Pharmaceutical: Buying The Projected Growth For 2026 - Seeking Alpha
- 14 days ago - Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference - GlobeNewsWire
- 21 days ago - Collegium Provides 2026 Financial Guidance and Business Update - GlobeNewsWire
- 4 weeks ago - Collegium Announces the Closing of $980 Million Syndicated Credit Facility - GlobeNewsWire
- 2 months ago - Collegium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Collegium Pharmaceutical: Another Solid Quarter - Seeking Alpha
- 2 months ago - Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance - GlobeNewsWire